Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection-Reference-Cited by-同舟云学术

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection

Published:2018-03-29 Issue:8 Volume:67 Page:1198-1204
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Dubberke Erik R¹,Lee Christine H²³⁴,Orenstein Robert⁵,Khanna Sahil⁶,Hecht Gail⁷,Gerding Dale N⁸

Affiliation:

1. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri

2. Hamilton Regional Laboratory Medicine Program, Department of Pathology and Molecular Medicine, McMaster University, Ontario

3. Vancouver Island Health Authority, Victoria, British Columbia

4. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

5. Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix

6. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota

7. Division of Gastroenterology, Hepatology and Nutrition, Loyola University Medical Center, Chicago, Illinois

8. Edward Hines Jr. VA Hospital, Illinois

Funder

Rebiotix Inc.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/67/8/1198/25849346/ciy259.pdf

Reference38 articles.

1. Burden of Clostridium difficile infection in the United States;Lessa;N Engl J Med,2015

2. Emergence of Clostridium difficile-associated disease in North America and Europe;Kuijper;Clin Microbiol Infect,2006

3. Multistate point-prevalence survey of health care-associated infections;Magill;N Engl J Med,2014

4. The morbidity, mortality, and costs associated with Clostridium difficile infection;Kwon;Infect Dis Clin North Am,2015

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics;Gut Microbes;2024-09-03

2. Causal role of the gut microbiome in certain human diseases: a narrative review;eGastroenterology;2024-09

3. Fecal Microbiota, Live-jslm (RBL; REBYOTA®) for Prevention of Recurrent Clostridioides difficile Infection;Gastroenterology Nursing;2024-08-21

4. Fecal microbiota live – jslm (Rebyota™/RBL) for management of recurrent Clostridioides difficile infection;Future Microbiology;2024-07-11

5. Fighting against Clostridioides difficile infection: Current medications;International Journal of Antimicrobial Agents;2024-07